Essential Role for Signal Transducer and Activator of Transcription-1 in Pancreatic β-Cell Death and Autoimmune Type 1 Diabetes of Nonobese Diabetic Mice

  1. Sunshin Kim1,
  2. Hun Sik Kim1,
  3. Kun Wook Chung1,
  4. Seung Hoon Oh1,
  5. Jong Won Yun2,
  6. Sin-Hyeog Im3,
  7. Moon-Kyu Lee1,
  8. Kwang-Won Kim1 and
  9. Myung-Shik Lee1
  1. 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
  2. 2Department of Biotechnology, Daegu University, Kyungsan, Kyungbuk, Korea
  3. 3Department of Life Science, Gwangju Institute of Science and Technology, Gwangju, Korea
  1. Address correspondence and reprint requests to Myung-Shik Lee, Department of Medicine, Samsung Medical Center, 50 Irwon-dong Kangnam-ku, Seoul 135-710, Korea. E-mail: mslee{at}smc.samsung.co.kr

Abstract

OBJECTIVE—We have reported important roles for signal transducer and activator of transcription-1 (STAT1) in pancreatic β-cell death by cytokines in vitro. However, in vivo evidence supporting the role for STAT1 in natural type 1 diabetes has not been reported. We studied whether STAT1 plays an important role in the development of natural type 1 diabetes.

RESEARCH DESIGN AND METHODS—We produced nonobese diabetic (NOD)/STAT1−/− mice by backcrossing and studied the in vivo role of STAT1 in β-cell death and type 1 diabetes.

RESULTS—STAT1−/− islet cells were resistant to death by interferon (IFN)-γ/tumor necrosis factor (TNF)-α or IFN-γ/interleukin (IL)-1β combination. Cytochrome c translocation by IFN-γ/TNF-α was abrogated in STAT1−/− islet cells. The induction of X-linked inhibitor of apoptosis protein by TNF-α was inhibited by IFN-γ in STAT1+/− islet cells but not in STAT1−/− islet cells. Inducible nitric oxide (NO) synthase induction and NO production by IFN-γ/IL-1β were impaired in STAT1−/− islet cells. Strikingly, diabetes and insulitis were completely abrogated in NOD/STAT1−/− mice. Development of diabetes after CD4+ diabetogenic T-cell transfer was inhibited in those mice. STAT1−/− neonatal pancreata were not destroyed when grafted into diabetic NOD/BDC2.5 mice that developed CD4+ T-cell–dependent islet cell death. In NOD/STAT1−/− mice, autoreactive T-cell priming was not impaired, but Th1 differentiation was impaired. A janus kinase (JAK) 2 inhibitor upstream of STAT1 attenuated islet cell death by IFN-γ/TNF-α or IFN-γ/IL-1β and delayed diabetes onset in NOD/BDC2.5-SCID mice.

CONCLUSIONS—These data demonstrate a critical role for STAT1 in β-cell death, T-cell immunoregulation, and type 1 diabetes in vivo and suggest potential therapeutic values of STAT1 or JAK inhibitors in the treatment/prevention of type 1 diabetes.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 9 July 2007. DOI: 10.2337/db06-1372.

    Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db06-1372.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted June 29, 2007.
    • Received September 28, 2007.
« Previous | Next Article »Table of Contents